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Anti-drug antibodies
Accelerated blood clearance (ABC)
ContentsConjugation of polyethylene glycols (PEGs) to proteins or drug delivery nanosystems is a widely accepted
method to increase the therapeutic index of complex nano-biopharmaceuticals. Nevertheless, these drugs and
agents are often immunogenic, triggering the rise of anti-drug antibodies (ADAs). Among these ADAs, anti-PEG
IgG and IgMwere shown to account for efficacy loss due to accelerated blood clearance of thedrug (ABC phenom-
enon) and hypersensitivity reactions (HSRs) entailing severe allergic symptoms with occasionally fatal anaphy-
laxis. In addition to recapitulating the basic information on PEG and its applications, this review expands on the
physicochemical factors influencing its immunogenicity, the prevalence, features, mechanism of formation and
detection of anti-PEG IgG and IgM and the mechanisms by which these antibodies (Abs) induce ABC and HSRs.
In particular, we highlight the in vitro, animal and human data attesting to anti-PEG Ab-induced complement
(C) activation as common underlying cause of both adverse effects. A mainmessage is that correct measurement
of anti-PEG Abs and individual proneness for C activation might predict the rise of adverse immune reactions to
PEGylated drugs and thereby increase their efficacy and safety.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Polyethylene glycols (PEGs) are synthetic polymers with a great va-
riety of industrial andwelfare use [1,2]. As one of the few biocompatible
synthetic polymers approved by the US FDA as ingredient of food, cos-
metic and hygienic products it is all around in our daily life, and its reg-
ulatory acceptance for internal use gave rise to numerous medicinal
applications, among others as osmotic laxative, a fusogen repairing in-
jured nerves and cell membranes [3], suppressor of oxidative stress
[3] and promoter of axonal regeneration [3]. In focus of this review,
PEG is gaining increasing use in pharmacotherapy as the polymer of
choice for bioconjugation [1,2].
Regarding the latter application, covalent or non-covalent conjuga-
tion of PEG to therapeutic proteins, such as antibodies (Abs) and en-
zymes, or other macromolecular pharmaceuticals, e.g., nucleotides, or
drug delivery nanosystems (DDSs), such as liposomes, micelles,
dendrimers, polymeric nanoparticles (NPs), solid lipid NPs, increases
their hydrodynamic size and water solubility, thus decreasing their
self-aggregation and interactions with blood proteins and cells of the
mononuclear phagocyte system (MPS). The result is increased in vitro
and in vivo stability entailing longer storage time, decreased renal, pro-
teolytic and phagocytic clearance with consequent increase of circula-
tion time, reduction of adverse effects, an overall increase of
applicability and therapeutic index [1,2,4–13]. To date, ≥ 21 PEGylated
proteins, peptides, Ab fragments and oligonucleotides have been ap-
proved by the FDA for marketing (Table 1). The attached PEGs in
these drugs are in the 2–40 kDa range.
Nevertheless, all thesemedicinal benefits are notwithout a price. Al-
though the shielding of immunogenic epitopes on proteins initially led
to the belief that PEG is poorly immunogenic, recent progress in exper-
imental and clinical research with different PEGylated drugs revealed
the rise of anti-PEG IgM and IgG both in animal models and in patients.
These anti-drug Abs (ADAs)may neutralize the therapeutic effect of the
drug and thereby reduce its clinical efficacy and, in addition, these ADAs
may cause adverse immune effects, specifically an acceleration of the
blood clearance of the PEGylated drug (ABC phenomenon), resulting
in efficacy loss, and hypersensitivity reactions (HSRs) which can lead
to anaphylactic shock and death [23–26].
The goal of this reviewwas to recapitulate some basic information of
PEGand then to expand on the factors influencing its immunogenicity,
the prevalence, features, mechanism of formation and detection of
anti-PEG IgG and IgM, and the mechanisms by which these Abs induce
ABC and HSRs via complement (C) activation.2. PEG: structural features
PEGs are highly flexible linear or branched polymers in the 0.4-
40 kDa MW range, synthetized with different end-groups. One of the
end-groups is used for covalent attachment to free carboxy, amino, or
sulphydryl groups on macromolecules, on DDS or on linkers that bind
the PEG to DDS, such as phosphatidylethanolamine, via one of a variety
of chemically reactive functional groups (acrylate, methacrylate,
maleimide, dibenzocyclooctynol, vinyl sulfonate or vinyl or allyl ethers)
[3]. The other end-group is most frequently a methyl group (methoxy-
PEG), although hydroxy (–OH), amino (–NH3+), butoxy (–O-(CH2)3)-
CH3) and tert-butoxy (–O-(CH3)3) terminal endings are also used
[27,28]. Fig. 1 shows different presentations of the polymer.According to X-ray diffraction and other means of molecular model-
ing of PEG, the chain builds up from repeating S-shaped fragments, or S-
modules, consisting of 10 oxyethylene units [13] (Fig. 1). The imbedded
cavities along the polymermay accommodate H2O explaining its strong
hydrophilic character providing a water-shield around the anchor
nanostructure [13]. Obviously, this shielding effect depends on the
length of PEG, the end-groups and the distance of PEG grafts from
each other.
It is also known that in addition to Abs, a large number of other pro-
teins andmacromolecules in plasma also bind to PEGylated NPs and in-
fluence Ab binding [29, 30].3. The immunogenicity of PEGylated drugs
3.1. Physicochemical features influencing Ab induction
Free PEG, in solution exhibits no or very weak immunogenicity even
in the presence of Freund's adjuvant [31,32]. However, when conju-
gated to a macromolecule or a DDS, it becomes immunogenic, just as
small haptens become immunogenic when combined with a larger car-
rier [31,32]. The Ab response is not limited against different parts of PEG
but it is a combination of differential responses against the individual
components of the whole PEGylated nanostructure. Accordingly, the
immunogenicity of PEGylated drugs depends on numerous features of
the polymer and its carrier.
The critical polymer features include the length (MW), branching
and the chemical nature of the terminal end-group. In general, Abs in-
duced against backbone epitopes have weaker binding affinities than
those induced against the terminal end-groups, whose size and hydro-
phobicity are critical in determining the binding affinity [28]. In one ex-
ample for such differential formation of anti-PEG Abs, Sherman et al.
[27] reported that Abs elicited by hydroxy PEG-conjugated proteins
have similar affinity to both the methoxy PEG and hydroxy PEG, while
Abs induced by methoxy PEG-conjugated proteins recognize methoxy
PEG more effectively than hydroxy PEG. Among the frequently used
PEG end-groups the binding affinities of formed Abs increase in the fol-
lowing order: hydroxy (–OH) < amino (–NH3+) < methoxy (–O-
CH3) < butoxy (–O-(CH2)3)-CH3) < tert-butoxy (–O-(CH3)3) [27,28].
Yet another physicochemical factor that may influence immunogenicity
is the hydrophilicity of the NP core structure, for example a PEG-shell-
possessing polymeric micelle with hydrophobic inner core elicited
anti-PEG IgM response, while similarly PEGylated micelles with hydro-
philic core did not [33]. Nevertheless, none of the monoclonal or poly-
clonal anti-PEG Abs are absolutely end-group, linker, or backbone-
specific, they display distinct relative selectivities.
Beyond the PEG chain and end-group features, another basic deter-
minant of immunogenicity of PEGylated drugs is the chemical nature
of PEG-acceptor core structure, whether it is a protein, a polynucleotide
or DDS. This variable may determine the type of immune response in
terms of spectrumof Ab subtypes and kinetics of primary and secondary
Ab response. Notably, if the PEGylated carrier is a protein, immunoge-
nicity proceeds mostly in a T cell-dependent (TD) pathway [34], and
the intrinsic immunogenicity of the protein facilitates the secretion of
PEG-specific Abs in a cooperative manner. This phenomenon is exem-
plified by the immunogenicities of Omontys® and Krystexxa®
(Table 1) where the proteins themselves are immunogenic, but their
PEGylated formulations induce much stronger anti-PEG immune
Table 1
PEGylated drugs reaching advanced clinical trials or the market.
Trade names API Indication Producer Approval Ref to
immunogenicity
Jivi® 60K-PEG recombinant Factor VIII antihemophilic
factor
Hemophilia A Bayer 2018
Palynziq® 2K-PEG-rhu-Phenylalanine ammonia-lyase,
Pegvaliase-pqpz
Phenyl-ketonuria Biomarin 2018 [14]
Revolixys® kita 40K-PEG-RNA aptamer + reverse agent, a
Factor-IXa blocker, Pegnivacogin /Anivamersen
Anti-coagulation Regado/Tobira 2016 [15]
Adynovate® 20K-PEG-Factor VIII Antihemophilic Factor VIII Hemophilia A Baxalta 2015
Onivyde® 2K-PEG-Liposomal irinotecan hydrochloride
trihydrate
Metastatic pancreatic cancer Ipsen 2015
Plegridy® 20K-PEG-Interferon beta-1a Relapsing forms of multiple sclerosis. Biogen 2014
Movantic® <1K-PEG-Naloxegol Opioid-induced constipation AstraZeneca 2014
Omontys®b 40K-PEG-Erythropoietin-mimetic peptide,
Peginesatide
Anemia associated with chronic kidney disease Affymax/Takeda 2012 [16]
Sylatron™ 12K-PEG-Interferon alpha 2b Melanoma Merck 2011
Krystexxa®c 10K-PEG-Uricase, Pegloticase Gout Savient 2010 [17]
Cimzia® 40K-PEG-Certolizumab Rheumatoid arthritis, Crohn's disease, Axial
spondyloarthritis and psoriatic arthritis
Nektar/UCB Pharma 2008
Mircera® 30K-PEG- erythropoietin (epoetin) beta Anemia associated with chronic kidney disease Hoffman-La Roche 2007 [18]
Macugen® 40K-PEG-anti-VEGF aptamer, Pegaptanib Age-related macular degeneration Pfizer 2004 [19]
Somavert® 5K-PEG-rhuGH (human growth hormone),
Pegvisomant
Acromegaly Pfizer 2003
Neulasta® 20K-PEG-Granulocyte colony stimulating factor,
Pegfilgrastim
Neutropenia Amgen 2002 [20]
Pegasys® 40K-PEG-interferon alpha-2 Hepatitis C and B Hoffmann-La Roche 2001
PegIntron® 12K-PEG-interferon alfa-2b Hepatitis C and B Schering-Plough/Enzon, 2000
Doxil®/Caelyx® 2K-PEG-Liposomal doxorubicin HCl Cancer Alza 1995 [21]
Oncaspar 5K-PEGylated L-asparaginase, Pegaspargase Acute lymphoblastic leukemia Enzon 1994 [22]
Adagen® 5K-PEG-adenosine deaminase (bovine),
Pegademase
Severe combined immunodeficiency disease
(SCID)
Enzon 1990
a withdrawn from Phase III clinical trialsa; or marketing in the USb or EUc.
Fig. 1. Chemical details of PEG structure via different presentations. A, ethylene glycol,
green; B, linear polyethyleneglycol (PEG), green; C, 2-K-PEG-Phosphatidylethanolamine
(PE), red: oxygen, green: carbon atoms, white: H atoms; D, branched PEG, E, schematic
illustration of the atomic structure of linear PEG, gray: carbon atoms, white: hydrogen
atoms, red: oxygen. The figure was prepared by modifying illustrations in Refs. [8, 13]
and in web images accessible at google search “polyethylene glycol/images”, among
others, at links: https://en.wikipedia.org/wiki/Polyethylene_glycol and https://www.
oxiteno.us/what-is-polyethylene-glycol-peg-uses-side-effects/.
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response is so strong, that these drugs had tobewithdrawn fromclinical
use [17,23,24,35,36].
In contrast to the TD immunization, if the PEG anchor is a DDS, im-
munogenicity may proceed in a T cell-independent (TI) pathway with
a different kinetics and Ab spectrum. The underlying mechanisms of
these immunogenicities will be detailed later in Section 5.
3.2. Impact of PEG amount and surface topography on Ab induction
Beyond the above physicochemical features of PEG and its carriers,
the extent of PEGylation of different proteins and DDS is another critical
determinant of immunogenicity. Proteins can be covered with up to a
few molecules of PEG, usually not more than 3, while DDSs obviously
have much more sites for PEG conjugation. In the latter case, the vari-
able is not the number of polymers attached to the macromolecule,
but the density of PEG on the NP surface, often expressed as mole %.
Information on the relationship between immunogenicity and PEG
surface density is mainly available for PEGylated liposomes, where the
PEG molecules assume different spatial configuration depending on
grafting density. Specifically, a density of <4 mol% PEG2000 on lipo-
somes forms a 3–4 nm thick layer wherein the PEGmolecules are sepa-
rated on the vesicle surface, referred to as “mushroom” configuration.
Over about 9–10 mol% PEG2000 forms a 4–10 nm continuous PEG
layer, dubbed as “brush” configuration,where the PEG chainsmay inter-
act, and possibly intertwine with each other.
As for the influence of PEG density on the immunogenicity of
PEGylated drugs, the inverse relationship between the extent of
PEGylation and immunogenicity of proteins has been known since the
rise of PEGylation technology in the 1970s [37]. Nevertheless, the conse-
quences of anti-PEG immune responses to differently PEGylated drugs
is not so easy to predict, considering the large number of iterations of
chemical and topographical variables in membrane-attached PEG and
host immune factors. In one study demonstrating this complexity, Liet al. [38] reported that liposomes with low (3%) and high (9%) PEG
density induced similar extent of anti-PEG IgM following intravenous
injection, yet the vesicles with high density PEG induced faster
Fig. 2.Molecular details of Ab binding to PEG. The stick model based on X-ray diffraction
data shows the intercalation of the aromatic rings of amino acids in the variable region
on the Fab arms of 2 IgG molecules (green and magenta thin sticks) into the groves of
an S-shaped core PEG fragment consisting of 10 oxyethylene units, and to a satellite PEG
fragment (thick stics with yellow carbons and red oxygen). Bound water molecules
within the groves are shown as red spheres. Reproduced from Ref [13] with permission.
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in this example, the high density of PEG enhanced a secondary conse-
quence of immunogenicity, without affecting immunogenicity per se.
In addition to PEG surface density, PEG chain length affects the ex-
tent of anti-PEG Ab induction. As described above, the minimum MW
of an anti-PEG epitope on PEG was reported to be 750 Da with positive
relationship between the length of PEG and anti-PEG Ab induction [39].
Namely, PEG30,000-BSA and PEG20,000-OVA induced higher anti-PEG IgM
response compared with PEG2000-BSA and PEG5000-OVA. On the other
hand, PEG on nanoparticles, such as liposomes and adenoviruses, are
relatively short and their extension does not necessarily increase immu-
nogenicity anymore [39,40].
3.3. Impact of linker on immunogenicity of PEG
As mentioned in section 2, PEGylation is performed by various con-
jugation chemistries and linkers to optimize the solubility, immunoge-
nicity and biological function of the drugs [41]. The linker between
PEG and proteins/carriers might affect the immunogenicity of PEG. In
an earlier study by Poppenborg et al. [42] showed that both amide
and succinate bonds between PEG and asparaginase induced anti-PEG
Abs at similar extent following injection of PEG-asparaginase. Recently,
in addition to anti-PEGAbs, anti-succinate linker Abwasobserved in pa-
tients who suffered from HSRs to PEG-asparaginase [43].
3.4. Host immune and genetic factors influencing PEG immunogenicity
Among the host factors influencing Ab induction by PEGylated
drugs, the route and schedule of drug administration, presence of
preformed Abs and immune status of the patient are obviously critical.
In addition, there is apparently a genetic factor as well. Chang et al.
[44] have identified seven single-nucleotide polymorphisms (SNPs),
most prominently “rs12590237” localized in the variable segment of
immunoglobulin heavy chain gene to be significantly associated with
high prevalence and concentrations of natural (pre-existing) anti-PEG
IgM in the general population in China.
4. Features of anti-PEG Ab binding to PEG
Asmentioned, anti-PEG Abs have specificities to either the backbone
or the terminal end-groups of PEG, both having different binding char-
acteristics. The binding to the backbone has relatively low affinity, and
the number of bound Abs is limited by the length of PEG. Considering
the length and MW of an oxyethylene group (0.34 nm, 44 Da, respec-
tively), and the epitope size that the variable region of Fab covers
(2–3 nm) it can be estimated that approximately 3–6 oxyethylene
groups can bind one IgG molecule [13,28]. Thus, the most frequently
used 2-K-PEG can bind up to 8–15 IgG molecules, at least in theory
[13,45]. The actual number, however, depends on more preconditions,
such as Ab-binding by “satellite” PEGs, which are small, 1/3 S-module
PEG segments (i.e., 3 oxyethylene units) whose link to the core chain
cannot be identified (Fig. 2).
5. The adverse consequences of Ab binding to PEGylated drugs
Asmentioned, the clinical significance of PEG immunogenicity lies in
thepossibility that binding of anti-PEGAbs decreases the therapeutic ef-
ficacy and safety of PEGylated drugs. The therapeutic efficacy can be re-
duced either by blocking the drug's therapeutic effect in some way, an
effect referred to as neutralization. The other way may be the enhance-
ment of the drug's clearance, the ABC phenomenon, decreasing the
drugs bioavailability. Finally, hypersensitivity reactions (HSRs) repre-
sent a health risk, with potentially severe, life threatening or deadly
(pseudo)allergic reactions. The next subsections briefly recapitulate
these phenomena highlighting the role of anti-PEG Abs therein.5.1. The ABC phenomenon and involvement of anti-PEGAbs
The essence of the phenomenon is that in case of repeated i.v. injec-
tions of animals or man with a complex, nanoparticulate drug, such as
PEGylated proteins or NPs, the second and subsequent doses display
progressively decreasing circulation time, and hence, reduced efficacy.
Since its first report in 2000 [46], the ABC phenomenon has been in-
tensely studied in our group (TS-TI) and many of its details have been
clarified [25].
We established, among others, its presence and variable extent in
mice, rats [47], guinea pigs [48], minipigs [49] and beagle dogs [50], its
dependency on the drug type (liposomes, ovalbumin, micelles) and
chemical composition (phospholipids with different acyl chains and
charges, cholesterol and different PEGs) and physicochemical proper-
ties (surface charge and liposome size) of PEGylated NPs [51]. We
have studied and established the dependence of ABC on lipid dose (in-
verse correlation with dose) [52–54] and administration schedule (ad-
ministrations within 3 days to 4 weeks) [55,56]. Notably, high dose of
PEGylated liposomes administered as a first dose does not precondi-
tions for ABC upon repeated administrations but rather elicits immuno-
logical tolerance, or anergy of B cells in mice [54,57], and the effective
period for inducing ABC is 4–7 days after the first dose, beyond which
the phenomenon gradually vanishes over weeks [46,55,56]
Further studies identified the molecular mechanism of ABC in the
following major steps: proliferation and differentiation of specific B
cells in the marginal zone of the spleen in T-cell independent manner,
resulting in anti-PEG IgM formation, complement (C) activation,
opsonization by C3 fragments and clearance from systemic circulation
by cells of the MPS (Kupffer cells) [34,50,52,53,58–63] (Fig. 3). Of
note, the above time window for observing ABC is consistent with the
biological half-life of IgM (3 weeks) [64] and the causal role of
anti-PEG IgM in ABC via C activation and opsonization of PEGylated
liposomes [26].
Among the unexpected, sometimes counter-intuitive findings re-
garding the ABC phenomenon, the anti-PEG IgM response was found
to be not specific to PEGylated liposomes, since bare, non-PEGylated li-
posomes also induced the ABCphenomenon of a seconddose PEGylated
Fig. 3.Mechanism of accelerated blood clearance (ABC) phenomenon. Reproduced from Ref. [65] with permission.
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drugs (doxorubicin, oxaliplatin, mitoxantrone, topotecan) have been
found not to affect, decrease or increase the ABC response, depending
on dose and mechanism of cytotoxicity [57,58,66]. For example,
therapeutic doses of Doxil suppress the anti-PEG IgMproduction as a re-
sult of cytotoxicity on B cells, as there is no report that Doxil would be
immunogenic or cause efficacy loss because of the ABC phenomenon
[21,67,68]. On the other hand, Suzuki et al. [49] found that i.v. injection
of Doxil at low, subtherapeutic doses, triggers the ABC phenomenon
in various animal species. The importance of cytotoxicity in preventing
ABC is examplified by the finding that PEGylated liposomal Topotecan,
a cell cycle specific drug, exerts its inhibitory action on ABC only
in the S phase of the cell cycle, when B cells are responsive to
cytotoxicity [55,66].
5.2. Hypersensitivity reactions and involvement of anti-PEG Abs
The HSRs caused by PEGylated drugs are essentially the same as
caused by a great variety of i.v.medications without PEGylation, includ-
ing liposomal and micellar drugs, radiocontrast agents, biologicals, en-
zyme therapies, iron compounds, even small molecules [69–72]. The
mild to severe allergy symptoms arise shortly after the first treatment,
although reactions starting later, or after repeated treatments are also
observed. In most cases the problem spontaneously resolves, but occa-
sionally, the reaction can escalate into fatal anaphylaxis.
Onemechanism of HSR, arising as a consequence of C activation, has
been intensely studied and reviewed over the past 20 years [73–76]. The
C activation triggering the HSR (C activation-related pseudoallergy,
CARPA) can proceed via all three known pathways, i.e., the classical, al-
ternative and lectin. Free PEG (PEG-600), used to treat spinal cord in-
jury, can activate C in the absence of anti-PEG Abs via by the
alternative and lectin pathways [77], but the alternative pathway can
be involved in any way, even if the trigger mechanism proceeds via
the classical pathway, as an amplificationmechanism. In fact, recent ev-
idence highlight the causal role of anti-PEG Abs-triggered classical path-
way initiation of CARPA, at least for the case of PEGylated liposomes.
Notably, we have shown in pigs [78] that 2-K-methoxy-PEGylated lipo-
somes (called Doxebo), corresponding to liposome-encapsulated doxo-
rubicin (Doxil) without the drug, induced massive anti-PEG IgM
formation within 3 days, reaching peak between days 6–9 and titer de-
clining slowly over >6weeks (Fig. 4A). Testing the reactogenicity of the
same liposomes by i.v. injection during the period of seroconversion led
to fatal anaphylaxis within 2–3 min only in immunized animals, while
the reaction was minor in naïve control pigs (Fig. 4B) [78].The causal role of anti-PEG Ab-induced classical pathway C activa-
tion in pseudo-anaphylaxis in this study was suggested by the simulta-
neous elevation of the C terminal complex (sC5b-9), a C activation
byproduct, in the blood of pigs and rise of pulmonary arterial pressure,
an immediate cause of circulatory collapse and death (Fig. 5A). The fact
that Doxil can bind anti-PEG Abs and activate C through thismechanism
was recently proven in vitro and in vivo, showing sC5b-9 inducedmem-
brane damage with subsequent release of free doxorubicin from
PEGylated liposomal doxorubicin (Doxisome) following the addition
ofmonoclonal anti-PEG Abs [79]. Fig. 5B is a reproduction of the striking
electron microscopic image of membrane damage caused by the
binding of sC5b-9 to liposomes following the addition of monoclonal
anti-PEG Abs in the presence of serum C.
5.3. Experimental and clinical examples of anti-PEG Ab triggered adverse
effects feeding an immune stimulatory vicious cycle
The pig experiment described above, wherein anti-PEG IgM-
triggered C activation led to major HSR [78], provides a model for
those clinical observations wherein a PEGylated drug displayed severe
HSRs along with loss of efficacy and direct or indirect evidence of C ac-
tivation. Among the PEGylated drugs listed in Table 1, the followings
were reported to cause more or less severe HSRs: Doxil®/Caelyx® [21],
Oncaspar® [22,80], Neulasta® [20], Macugen® [19], Mircera® [18],
Palynziq® [14], Omontys® [16], Krystexxa® [17] and Revolixys®
[15,81–83], leading to market withdrawal of the last 3 medicines.
Among these reactogenic drugs significant formation of anti-PEG Abs
and/or treatment failure and/or C activation were described for
Oncaspar® [17,23,24,35,36] and Revolixys® [15, 81-83].
Considering the known causal relationships among C activation,
ABC, HSRs, opsonization and immunogenicity, we proposed thepossible
rise of an immune stimulatory vicious cycle among these effects (Fig. 6),
a concept [26,84] consistent with some of the above listed clinical
observations.
6. Mechanism of formation of natural and induced anti-PEG Abs
[16,17]
Asmentioned in the section onphysicochemical features influencing
Ab induction (3.1.), the immunogenicity of PEGylated drugs may be TD
or TI, dependingon the chemical nature of PEG-anchormolecule or DDS.
PEGylated proteins induce immune responses mainly via the classical
TDmanner, while PEGylated NPs, like PEGylated liposomes, may induce
Ab production via TI immunogenicity. However, neither of these
Fig. 4. Correlation between immunogenicity and PEGylated liposome-induced pseudo-anaphylaxis in pigs. A) Immunogenicity of Doxebo: Time course of anti-PEG IgM and IgG levels in
blood, expressed as log titer. B. Changes of systemic and pulmonary arterial blood pressures (SAP, PAP) in pigs immunizedwith Doxebo 3weeks earlier. The lethal anaphylactic reaction is
reversed by epinephrine with heart massage. Figures reproduced from Ref. [78].
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mal vaccine-induced primary and secondary immune responses [7].
Fig. 7 illustrates the kinetics of typical protein-induced immunoge-
nicity, characterized by a start of specific IgM production around day 5
and peak at about day 10. The rise and peak of IgG following isotype
switching during the primary response is delayed by about 5 days,
and the extent of IgG secretion slightly exceeds that of IgM. In contrast,
during a secondary response, the IgM production is less and is followed
by subtype switch with a rise and peak of IgG at around 11 and 15 days,
respectively. During the secondary response the IgM production lessens
while the IgG response starts and peaks earlier at a substantially in-
creased quantity.
The TD immunogenicity to PEGylated proteins differs from the
above scheme. For example, in rabbits, PEGylated human IFN-α,
human serum albumin or porcine uricase, used as immunogens to-
gether with complete (1st injection) and incomplete (1, 2, 4, 8,
10weeks later) Freund's adjuvant led to the production in 2 weeks pre-
dominantly IgG Abs [27,28]. In our previous study, anti-PEG IgM was
produced from day 5 and reached a peak at day 7 following single injec-
tion of PEGylatedOVA (ovalbumin, themain protein found in eggwhite,
a TD antigen) inmicewithout secretion of IgG [34]. In humans, anti-PEG
IgG was detected in 37% of patients after a single i.v. injection of
pegloticase [85]. As mentioned, protein anchors of PEGs may enhance
the immunogenicity of PEG by presentation of its peptides by PEG-specific B cells to helper T cells [86,87]. Therefore, anti-PEGAb induction
by TD antigens varywith carrier proteins, the presence of adjuvants and
species.
TI immunogenicity, which has been proposed to be the mechanism
of PEGylated liposome-induced Ab induction, is typical of repetitive
structures. Studies from our (TS-TI) laboratory point to this mechanism
underlying the immunogenicity of PEGylated DDS [52,60,64,78]. The
process is localized to B cells in the marginal zone of the spleen
[52,60,64] and is characterized by onlyminor IgG response running par-
allel with massive IgM production, with lack of isotype switching and
absence of secondary response.
An example for this type of immune response, obtained in pigs, was
shown in Fig. 4A. Fig. 7B and C show themurine prototype of this immu-
nogenicity, wherein maximal rise of anti-PEG IgMwas observed within
5 days after i.v. injection of PEGylated liposomes in mice followed by a
decline to near baseline level in 2–4weeks (Fig. 7B). This was paralleled
with a smaller rise of anti-PEG IgG (Fig. 7C)without secondary response
despite repetitive weakly immunization over 6 weeks (Fig. 7C).
As for themolecularmechanismof TI immunogenicity, the phenom-
enon has been attributed to a subset of B cells specialized for rapid and
massive IgM production in response to foreign antigens. These IgM
memory B cells, also called natural memory or natural effector memory
B cells, derive from a particular developmental pathway characterized
by somatic hypermutation. Thus, their Ig heavy chain repertoire differs
Fig. 5. Evidence for anti-PEG Ab-mediated C activation in pigs in vivo (A) and in human
serum, in vitro (B). Panel A shows the changes of pulmonary arterial pressure (PAP) and
sC5b-9 following i.v. injection of Doxebo in animals immunized with Doxebo a week
before. The paralleling courses of rapid rise and slower decline of these variables on the
minute time scale reflect close correlation between liposome-induced cardiopulmonary
distress and C activation. Reproduced from Ref. [78] with permission. In B, human
serum was incubated with PEGylated doxorubicin-containing liposomes (Doxisomes)
together with a monoclonal anti-PEG IgG. The cryo-EM image shows the damage of
liposomal bilayer (black arrows) following incubation of vesicles with human serum in
the presence of anti-PEG IgG. White arrow: intact bilayer. Scale bar represents 25 nm,
reproduced from Ref. [79] with permission.
Fig. 6. Complement-activation fed immune stimulatory vicious cycle. The cycle starts with
C activation by PEGylated drugs entailing anaphylatoxin (C3a, C5a) release that causes
HSRs, i.e. CARPA. The other consequence of C activation, opsonization of PEGylated
drugs by C3b and its derivatives (C3dg and C3d), explains their ABC. C activation, a
known “bridge” between innate and specific immunity, enhances the rise of anti-PEG
Abs which bind to the drugs further enhancing C activation and ABC to close the cycle.
Reproduced from Ref. [84] with permission.
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they make about 25% of B cells in the peripheral blood [44], while in ro-
dents, they have been localized at the marginal zone of spleen follicles
[57,63,88,89]. Marginal zone B cells react with polymeric antigen
through crosslinking of B cell receptor, entailing rapid, but low affinity
Ab production without help of T cells. Thus, PEGylated liposomes can
massively produce anti-PEG IgM within 5 days. However, the affinity
of anti-PEG Ab may be different between TD and TI antigens. We have
recently demonstrated [34] that anti-PEG IgM induced by PEGylated
OVA cleared both PEGylated OVA and PEGylated liposomes from
blood, but that induced by PEGylated liposomes cleared only PEGylated
liposomes. This suggests that the anti-PEG IgM secreted from marginal
zone B cells without help of T cells in response to PEGylated liposomes
have low avidity, resulting in weak clearance of PEGylated OVA.
Fig. 8 shows a scheme of possible steps whereby PEGylated lipo-
somes induce TI immunogenicity in the marginal zone of spleen folli-
cles. The PEG on liposomes bind to receptors (BCR) on these IgM
memory B cells that express specificity against PEG. The size of lipo-
somes and configuration of PEG on their surface fits in-between 2 or 3
specific B cell receptors and crosslink them to trigger an intracellular
signal cascade leading to the proliferation of PEG-specific B cells anddifferentiation to plasma cells with production and release of specific
anti-PEG IgM into the blood [90].
7. Pre-existing (natural) anti-PEG Abs in healthy humans
In addition to post-immunization, anti-PEG Abs are also observed in
healthy subjects without any prior exposure to PEGylated drugs or
agents. These are referred to as pre-existing, or natural anti-PEG Abs
whose prevalence in the normal human population seems to increase
over time. In particular, the prevalence of Ab+ individuals in the healthy
population was estimated to be 0.2% in 1984 [32], 25% in 2012 [91] and
about 40% in 2016 [92]. This increase may be due to an improvement of
the limit of detection of Abs over time and to greater exposure to PEG.
Regarding the latter option, Yang et al. [56] pointed to the fact that the
skin is always exposed to external stimuli, which causes inflammatory
responses and immune cell recruitment. Under such conditions, daily
use of PEG applied to skin might activate recruited immune cells,
resulting in the induction of pre-existing anti-PEG Abs. Keeping with
the idea of transcutaneous immunization, we recently found in hairless
rat that daily skin exposure to a PEG-containing cosmetic, but not sham-
poo and sunscreen, induced anti-PEG Abs whose level corresponded to
that induced by PEGylated liposomes (unpublished data). Accordingly,
daily exposure to cosmetics, toothpaste, shampoos, sunscreens, that
contain some forms of PEG,might contribute to the increase of the prev-
alence of pre-existing anti-PEG Abs, although a role of oral immuniza-
tion with PEG-containing soft drinks and internally taken medicines
cannot be excluded, either. This multifactorial background of anti-PEG
Ab formation also explains the substantial individual variation of anti-
PEG Ab titer in blood [23,24,81,82,91,93], with very high values ob-
served in a small fraction (up to 10%) of humans [93].
8. Strategies to suppress PEG immunogenicity
Based on all above possible problems arising from the immunoge-
nicity of PEG, it is clear that reducing or eliminating this effect will be
necessary for successful clinical applications of some PEGylated
nanodrugs. Accordingly, there is substantial research effort to find
ways to achieve this goal [94,95]. The approaches showing more or
less success include structural modification of the PEG moiety, for ex-
ample by replacing methoxy PEG with other functional groups, such
as amino (-NH2), carboxyl (-COOH) and hydroxyl (-OH), or using alter-
native polymers, such as polyvinyl alcohol, polyvinyl-pyrrolidone or
polyacrylamide instead of PEG. Yet, for liposomes, another approach is
the insertion of gangliosides into the bilayer beside PEG, which sup-
presses the immune response. However, perhaps the easiest approach
Fig. 7. Features of typical protein-induced T cell-dependent (A) and PEGylated liposome-induced T-cell independent (TI) immuogenicities inmice (B and C). A is a textbook illustration of
typical Ab response to protein antigens. B shows anti-PEG IgM production up to 6 weeks following a single i.v. injection of PEGylated liposomes while C presents the anti-PEG IgM
production following sequential injections with PEGylated liposomes six times in 7-day intervals in mice,. In C, the closed column represents anti-PEG IgM, and the open column
represents anti-PEG IgG. Reproduced from Ref. [60] with permission.
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prolongation of the time interval between injections, since TI immuno-
genicity may be short-lived [25,26,65,78].
9. Anti-PEG Ab assays
9.1. Assay types and their features
As summarized in Table 2, the earliest method, passive hemaggluti-
nation, is rapid and simple, but not sufficiently sensitive and quan-
titative. To achieve increased sensitivity, Western blot, acoustic
membranemicroparticle technology (AMMP), enzyme immunosorbentassay (ELISA) and flow cytometry can be used, which amplify the signal
by using enzyme reactions or fluorescence. However, these techniques
are usually not quantitative in absolute terms, and the detection limits
depend on experimental conditions. The surface plasmon resonance
(SPR) technology is ultrasensitive, quantitative and fast, but themethod
is not common due to the special and expensive instrument and
reagents needed.
9.2. Anti-PEG ELISA: formats and limitations
Overall, ELISA is the most widely applied technique to detect anti-
PEG Abs due to its high sensitivity and capability to quantify Ab levels
Fig. 8. Molecular mechanism of TI immunogenicity by PEGylated liposomes in splenic marginal-zone IgM memory B cells. Scheme based on Refs. [57, 63, 88–90].
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generated by enzyme-conjugated host IgG or IgM specificAbs recogniz-
ing PEG-specific Abs in serum or plasma bound to a PEG coated surface.
In bridge-format ELISAs [102], PEG specific surface bound anti-PEG Abs
are detected via the conjugated antigen, rather than anti-host IgG or
IgM. Thus, the anti-PEG Abs are wedged inbetween two layers of
PEGylated antigen due to these Abs' bi- or multivalency: the 1st one is
coated on the surface for capture and the 2nd, most often biotinylated
antigen, is preincubated with the sample for ultimate detection by a
streptavidin-enzyme conjugate. The advantage of bridge ELISAs over di-
rect ones is obvious when immunogenicity of chimeric, humanized, or
fully human monoclonal Ab-based drugs are measured whereupon a
cross reactivity of conjugated anti-human IgG or IgM with the plate-
bound antibody drug cannot be excluded [98]. However, in absence of
such danger in case of anti-PEG Abs, the bridge assay, which involves
more steps, may have no advantage over the direct ELISA [102]. The
use of competitors is also popular in direct systemswherein the concen-
tration of competitors is measured at a constant serum dilution, usually
that inhibits 50% of the maximal binding [27].
A main limitation of anti-PEG ELISAs lies in their questionable valid-
ity to in vivo conditions in light of the likely difference of the Abs' avidity
to different PEGylated formulations in vivo and in the test system,
in vitro. In particular, the ELISA cannot truly reflect the binding condi-
tions in blood, since the binding of Abs to flat plate-attached PEG anti-
gens is unlikely the same as the binding in plasma to protein- or DDS-
attached PEG.9.3. Anti-PEG ELISAs: considerations for standardization
As mentioned above, there is no “gold standard” or “authentic cali-
bration standard” that could quantify the exact avidity, and, hence,
amount of anti-PEG Abs that bind in vivo to PEGylated drugs. There
are several reasons for this shortcoming. One is that PEGs on proteins,
DDS and plate-bound anchor structures are likely to have different
primary-, secondary- and tertiary structures implying, in analogy to
proteins, the length, branching and intra- and inter-molecular bonds
that stabilize the polymer in space. Yet other variables that cannot be
reproduced in a standard include the binding of additional proteins to
the PEGylated NPs that have an impact on Ab binding and the variations
of individual immune responses to PEGylated drugs. The latter circum-
stance ismanifested in different combinations of anti-PEG Ig classes and
IgG subclasses in individual samples, each having different binding
characteristics. For all these reasons there is much work ahead to de-
velop a quantitative anti-PEG ELISA for universal use.At present, the most widely used approach to estimate anti-PEG Ab
levels in away that enables inter-experimental comparisons is titration,
which involves the measurement of the dilution where the Ab binding
signal reaches the baseline or a preset lower limit value. However, titra-
tion assays also depend on test specifics, such as the coating and the de-
tergent used in the ELISAs. To illustrate with an example, in the most
commonly used anti-PEG ELISAs, DSPE- or BSA-conjugated PEGs are at-
tached to the surface of ELISA plates by either drying (using alcohol as
solvent) or letting the adherence spontaneously proceed due to second-
ary intermolecular forces (e.g. using plates with different hydrophobic-
ity). Plates with apolar surface coating, like the Polysorp (Nunc) plates,
preferentially bind the hydrophobic DSPE part of PEG-DSPE antigens via
WanderWaals forces, providing better access of Abs to the PEGpart rel-
ative to plates with hydrophilic coatings, such asMaxisorp plateswhich
tend to attract the hydrophilic PEG portion. For the same reason, the
length of PEG is critical for Ab access to the different epitopes on PEG.
It seems that 2 kDa PEG is sufficiently long to provide reproducible re-
sults when an apolar binding surface is used.
Yet another critical assay variable is the detergent used in the
blocking and washing steps to reduce unspecific absorption of pro-
teins to the plate and the antigen during ELISA [103]. The issue was
raised by questioning the use Tween-20 (polysorbate), a widely ap-
plied non-ionic detergent, for anti-PEG Ab detection since it contains
polyoxyethylene (in addition to sorbitan monolaurate) which may
compete with PEG for Ab binding [92]. The authors suggested the
use of zwitterionic 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) instead, which is a common surfactant
in electrophoresis and isoelectric focusing. However, we have used
Tween-20 in an ELISA measuring anti-PEG IgM in pig blood [78]
and obtained no evidence for Tween 20's interference with anti-
PEG Ab detection. As shown in Fig. 9, measuring of anti-PEG IgM
with ELISA using 0.1% Tween-20 gave a low (0.6) (Fig. 9A) and
high (1.4) (Fig. 9B) signal (A450 was 0.6 and 1.4, in naïve and a
PEGylated liposome (Doxebo)-immunized pigs, respectively) at the
lowest dilution for these samples, which is consistent with effective
immunization of the animal against PEG. Importantly, the high signal
at low dilution in Fig. 9B decreased upon increasing the dilution, and
it showed dose dependence, 0.1% Tween-20 giving higher signal
than 0.05 or 0.01%. Such dilution and dose dependence of anti-PEG
Ab measurement could not be seen if Tween-20 interfered with the
assay. Moreover, the experiment in Fig. 9 also shows the unique util-
ity of Tween-20, since its omission from the medium eliminated the
capability to dilute out the A450 signal. Notably, the experiment in
Fig. 9 showed greatest sensitivity with 0.05% Triton X-100, which
may be a useful information for future studies.
Table 2
To analyze the immunogenicity of PEG, a great variety of techniques are available whose main features has been tabulated in order of increasing sensitivity (Table 2).
Method Test principle Detection limit* Advantages Limitations Ref.
Passive
hemagglutination
Erythrocyte surface is modified with
methoxyPEG (or other PEG derivative)
and mixed with serial dilutions of test
serum. In the presence of anti-PEG Abs,
the erythrocytes agglutinate which can
be followed easily. Titer is defined as
the highest serum dilution giving
complete hemagglutination.
No information Relatively fast and inexpensive assay.
PEGylated erythrocytes may be similar
to membrane attached PEG derivatives,
therefore they model the
immunogenicity of larger PEGylated
NPs (e.g., liposomes).
It cannot discriminate Ab isotypes.




Dye-conjugated PEGylated antigen (e.g.
PEGylated liposome) is incubated with
samples (serum). Ab-antigen complex
is enriched by gel filtration. Finally, the
dye containing fraction is subjected to
SDS-polyacrylamide gel
electrophoresis, transferred onto
nitrocellulose membrane, and anti-PEG
Abs are identified and visualized by
enzyme reaction after recognizing them






It models the physiological
PEG–anti-PEG Ab interaction inasmuch
as the same soluble antigen could be
used for detection than for Ab
generation (e.g. PEGylated liposomes).
As a consequence, functionally active
and important Abs are detected. It can
discriminate anti-PEG Ab isotypes.
It consists of several steps, which
might decrease the accuracy of the
measurement.
For Ab-antigen enrichment step,
antigen must be stained, which
might not be obvious. There is no






Samples are diluted and incubated with
paramagnetic beads coated with
methoxyPEG to capture anti-PEG Abs.
The complex is captured on an acoustic
membrane coated with Protein A. The
change in mass on the membrane
results in a signal proportional to the
mass of anti-PEG Abs.
1 μg/mL anti-PEG
IgG
This method provides absolute results. Protein A binds mainly IgG, thus the








The common feature of these tests is
that PEG-containing antigen is attached
somehow to a 96-well plate, which
captures PEG specificmAbs from the
test samples. Thereafter Abs are
visualized by enzyme reaction after
they are recognized by conjugated
antigens (bridging type) or antibodies
(or other detetector molecules).
Further details are discussed below (in
9.2 and 9.3)
100 ng/mL level of
anti-PEG Abs
It has relatively high sensitivity
It provides reliable and quantitative
anti-PEG Ab detection.
It is the most widely applied technology
for anti-PEG Ab quantitatioin
It can discriminate among Ab isotypes.
It does not require expensive and
special equipment. A substantial
knowledge about PEG-Ab interaction is
originates from this method.
Concentration needs to be calculated
by serial dilution of a standard.
However, it is not possible to
produce an Ab standard whose
binding affinity (avidity)_ to the
plated antigens is the same as the
Abs in the sample. Therefore, the
assays provide relative values
instead of concentration in absolute
terms. Hence, there is wide variation
in the literature regarding anti-PEG
Ab units and value ranges.
[98–100]
Flow cytometry PEG is grafted on a polymer matrix,
such as TentaGel-OH polystyrene
microparticles. After washing steps,
particles are stained for bound IgG
and/or IgMwith fluorescent dye labeled
anti-IgG and/or IgM. The mean
fluorescence intensity of particles is
determined by flow cytometry.
It is not known
exactly. Detection
limit of a FACS
based bead array is
10–5000 pg/mL.
It can discriminate anti-PEG Ab
isotypes. It has great potential because
of the high sensitivity of measurement.
PEG is presented by a polymer
matrix instead of its
treatment-relevant support
(i.e., NPs), therefore the binding
conditions are different; the
obtained values do not necessarily





A PEG-functionalized polymer is
immobilized onto SPR sensor chips for
capturing anti-PEG Abs from the
samples flown through the sensor units.
Bound anti-PEG Abs are quantified by
wavelength shift proportional with the
amount of Ab bound to the sensor chip.
1 ng/mL anti-PEG
Abs
It is a highly sensitive measurement
with low background, enabling
quantification of anti-PEG Abs in
absolute concentration.
It can discriminate anti-PEG Ab
isotypes.
SPR is a powerful label-free
technique to monitor
biomolecule-surface interactions.
However, it requires a special,
expensive instrument, and like other
methods using flat or matrix support
for PEG, the measurement does not
necessarily mimic the in vivo
interactions (avidity) of Abs with
protein or NP-conjugated PEG
[101]
Measurements are ranked in descending order according to their estimated detection limit. However it must be emphasize that real detection limit is dependent from test details, partic-
ular in the case of Western Blot and ELISAs.
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Ab binding, the most likely explanation lies in the substantial structural
differences between this surfactant and 2K-PEG-DSPE, the antigen used
to coat the ELISA plate in our assay [78]. Tween-20 consists of 5 ethylene
oxide units at 4 different sites on the moleculewhile 2K-PEG-DSPE con-
tains 46 ethylene oxide units in a raw (Fig. 1), implying entirely differ-
ent epitope exposure for Ab binding.
The message from the above example is that one needs to be cau-
tious tomake predictions and extrapolations regarding technical details
and results in one particular anti-PEG ELISA to another, and that each
ELISA test benefits from thorough validation before making generalizedconclusions. At least until a gold standard anti-PEG assay will become
available.
10. Conclusions
The immunogenicity of PEGylated drugs is critical to the
therapeutic success and safety of an expanding number of nano-
biopharmaceuticals. In order to reduce the risk of the ABC phenomenon,
whichmight decrease the therapeutic effect upon repetitive treatments,
as well as the risk of CARPA, which may cause severe HSRs with poten-
tial death, it seems useful to test patients for natural anti-PEG Ab titers
Fig. 9. Plasmadilution-dependent readings [A(450)] of porcine anti-PEG IgM specific direct ELISAs using 0.01, 0.05, 0.1% Tween-20, or 0.05% TritonX-100 surfactants or nodetergent in the
washing and incubation steps. Experimental details are in Ref. [78] “NSB”means non-specific binding, obtained in wells that were not coated with antigen.
173G.T. Kozma et al. / Advanced Drug Delivery Reviews 154–155 (2020) 163–175and proneness for C activation in their blood samples prior to and/or
after treatmentwith a PEGylated drugs [26]. Likewise, testing of the im-
munogenicity of PEGylated drugs in animal models that are sensitive
not only to ABC phenomenon but also to the anaphylactic activity of
the drugs, such as the pig “CARPA” assay [78,104] could flag potentially
strong immunogenicity in man. Needless to emphasize, scientific re-
search into these problems will hopefully unveil more details of these
adverse immune effects and thus suggest more preventive measures
in the future.
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